Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and the United Kingdom. The company provides EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation, and monitoring of 3D genomic biomarkers to diagnose patients. Its products include EpiSwitch Prostate Screening Test (PSE), a prostate cancer screening test; EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting therapeutic response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.

Oxford Biodynamics PLC

Dr. Jon Anthony Joseph Burrows B.Sc., M.Sc., Ph.D.

CEO & Executive Director

Mr. Paul Leslie Stockdale F.C.A., M.A.

CFO & Executive Director

Dr. Alexandre  Akoulitchev M.A., Ma (Oxon), Ph.D.

Chief Scientific Officer & Executive Director

Mr. Thomas G. Guiel B.A.

Chief Operating Officer

David  Blum

Senior Vice President of Marketing

Dr. Steven  Arrivo

Senior Vice President of Business & Corporate Development

Dr. Ewan  Hunter B.Sc., Ph.D., Ph.D., (KCL)

Chief Data Officer

T.  Demain

Company Secretary

Oxford Biodynamics PLC (OBD) Stock Analysis, Discussion Forum and Financial Metrics - LSE Exchange

Oxford Biodynamics PLC (OBD) Earnings Report Date and History | LSE

OBD's next earnings is on January 15, 2025 (Before Market Open)

When is the earnings report for OBD?

OBD Earnings History

OBD Stock Discussion Forum and Message Board

News for LSE: OBD